Sertraline

Sertraline is an antidepressant that works by slowing the brain's reuptake of serotonin, a chemical messenger involved in mood regulation. By keeping more serotonin available in the spaces between nerve cells, it can help lift low mood and reduce repetitive worrying thoughts. It's commonly prescribed for depression, obsessive-compulsive disorder, panic disorder, social anxiety disorder, and premenstrual dysphoric disorder. In Australia it's approved for children aged six and older when used for OCD.

The medication takes time to build up in the body—its half-life is around 26 hours, meaning roughly a day passes before half of a dose clears—so effects aren't immediate and stopping suddenly can cause withdrawal symptoms. Your family member may start to feel some benefit after a few weeks, though full effects can take longer.

Common side effects include trouble sleeping, tremor, drowsiness, dizziness, diarrhoea, nausea, fatigue, and headache. Many of these settle as the body adjusts, but if they persist or are distressing, the prescribing doctor should know. Serious side effects are rare but include changes in mood or suicidal thoughts (particularly early in treatment or after dose changes), heart rhythm changes, liver problems (watch for yellowing skin or eyes, dark urine), severe skin reactions, and a rare condition called neuroleptic malignant syndrome (high fever, muscle rigidity, confusion). Seek urgent medical help if any of these occur.

Sertraline can't be taken with certain other medicines, particularly MAO inhibitors (a different type of antidepressant), pimozide, or within two weeks of stopping an MAOI. At lower doses sertraline has less effect on the liver enzyme CYP2D6 than some other antidepressants, but it can still interact with other medicines metabolised through that pathway, so the prescribing doctor needs a full medication list.

A Behaviour Support Practitioner reviewing sertraline will want to understand whether it's being used to manage distress or mental health symptoms in their own right, or whether it's being relied on primarily to suppress behaviours of concern. If your family member's challenging behaviours are ways of communicating unmet needs—pain, sensory overload, frustration—and sertraline is dampening those signals without addressing the underlying cause, it may meet the threshold for chemical restraint. The review looks at whether non-medication supports have been tried, whether the dose and duration are appropriate, and whether the person's quality of life and ability to participate in daily activities have genuinely improved.

Sertraline is a selective serotonin reuptake inhibitor with potent and highly selective inhibition of neuronal serotonin reuptake and only very weak effects on noradrenaline and dopamine pathways. It holds TGA indications across major depressive disorder, obsessive-compulsive disorder (including paediatric OCD from age six), panic disorder, social anxiety disorder (treatment and relapse prevention), and premenstrual dysphoric disorder. The average terminal elimination half-life is approximately twenty-six hours. At lower doses sertraline exhibits less prominent CYP2D6 inhibitory activity than some other SSRIs, though clinically important 2D6 inhibition remains possible; this profile matters when co-prescribed agents have narrow therapeutic indices metabolised via that pathway.

Common tolerability issues include insomnia, gastrointestinal upset (diarrhoea, nausea), tremor, somnolence, dizziness, headache, and fatigue. Serious adverse events documented in the Product Information include neuroleptic malignant syndrome, suicidal ideation, QTc prolongation and torsade de pointes, serious hepatic events (hepatitis, jaundice, liver failure), and rare exfoliative skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis). Sertraline is contraindicated in known hypersensitivity, concomitant pimozide use, and concurrent or recent (within fourteen days) MAOI therapy; at least fourteen days must elapse after stopping sertraline before initiating an MAOI.